{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:27:33Z","timestamp":1794432453454,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["R016620002"],"award-info":[{"award-number":["R016620002"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119821","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:34:21Z","timestamp":1785936861000},"page":"119821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PARP inhibition induces a redox-dependent dormant reservoir vulnerable to disulfiram in high-grade serous ovarian cancer"],"prefix":"10.1016","volume":"202","author":[{"given":"Sutthipun","family":"Suriya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-8136","authenticated-orcid":false,"given":"Supawan","family":"Jamnongsong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanettee","family":"Jamyuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwanit","family":"Therasakvichya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7783-6103","authenticated-orcid":false,"given":"Somponnat","family":"Sampattavanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2026.119821_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hoc.2018.07.007","article-title":"Mechanisms of drug resistance in high-grade serous ovarian cancer","volume":"32","author":"Freimund","year":"2018","journal-title":"Hematol. \/Oncol. Clin."},{"issue":"12","key":"10.1016\/j.biopha.2026.119821_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119821_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"issue":"10106","key":"10.1016\/j.biopha.2026.119821_bib4","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2026.119821_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119821_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1504084","article-title":"Survival analysis of recurrent ovarian cancer under different PARP inhibitor treatment patterns: a single-center retrospective study","volume":"14","author":"Shen","year":"2025","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119821_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119821_bib8","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2026.119821_bib9","article-title":"Dormant and activated polyploid giant cancer cells: from chemoradiotherapy resistance to cancer progression","author":"Liu","year":"2025","journal-title":"Cancer Lett."},{"issue":"29","key":"10.1016\/j.biopha.2026.119821_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf7195","article-title":"Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci. Adv."},{"issue":"15","key":"10.1016\/j.biopha.2026.119821_bib11","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"C ombination A TR (ceralasertib) and PARP (olaparib) I nhibitor (CAPRI) trial in acquired PARP inhibitor\u2013resistant homologous recombination\u2013deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119821_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241298329","article-title":"Update on combination strategies of PARP inhibitors","volume":"31","author":"Lin","year":"2024","journal-title":"Cancer Control."},{"issue":"811","key":"10.1016\/j.biopha.2026.119821_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adu6989","article-title":"Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer","volume":"17","author":"Jiao","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119821_bib14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biom13101480","article-title":"Combination treatment strategies to overcome PARP inhibitor resistance","volume":"13","author":"Soung","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib15","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1038\/s41467-019-10460-1","article-title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","volume":"10","author":"Fleury","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-022-00339-8","article-title":"Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer","volume":"6","author":"Perez-Villatoro","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119821_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"issue":"7","key":"10.1016\/j.biopha.2026.119821_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306969","article-title":"Polyploid giant cancer cells induced by Docetaxel exhibit a senescence phenotype with the expression of stem cell markers in ovarian cancer cells","volume":"19","author":"Zhao","year":"2024","journal-title":"Plos. One"},{"issue":"10","key":"10.1016\/j.biopha.2026.119821_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105182","article-title":"Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma","volume":"25","author":"Jamnongsong","year":"2022","journal-title":"Iscience"},{"issue":"3","key":"10.1016\/j.biopha.2026.119821_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cpch.9","article-title":"Reverse phase protein arrays for compound profiling","volume":"8","author":"Moerke","year":"2016","journal-title":"Curr. Protoc. Chem. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119821_bib21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/bioinformatics\/bty060","article-title":"L1000FWD: fireworks visualization of drug-induced transcriptomic signatures","volume":"34","author":"Wang","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2026.119821_bib22","doi-asserted-by":"crossref","DOI":"10.7717\/peerj-cs.623","article-title":"The coefficient of determination R-squared is more informative than SMAPE, MAE, MAPE, MSE and RMSE in regression analysis evaluation","volume":"7","author":"Chicco","year":"2021","journal-title":"Peerj Comput. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib23","doi-asserted-by":"crossref","first-page":"3.1","DOI":"10.14405\/kjvr.20210040","article-title":"Synergistic anticancer activity of disulfiram\/copper against mouse lymphoma cells","volume":"62","author":"Jung","year":"2022","journal-title":"Korean J. Vet. Res."},{"issue":"W1","key":"10.1016\/j.biopha.2026.119821_bib24","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119821_bib25","first-page":"243","article-title":"Methods to monitor ROS production by fluorescence microscopy and fluorometry","volume":"542","author":"Wojtala","year":"2014"},{"issue":"5","key":"10.1016\/j.biopha.2026.119821_bib26","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1042\/BST20221431","article-title":"The molecular mechanisms of diapause and diapause-like reversible arrest","volume":"51","author":"Easwaran","year":"2023","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-011-1692-y","article-title":"Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells","volume":"133","author":"Croker","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2026.119821_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbi.2014.12.008","article-title":"N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes","volume":"234","author":"Morgan","year":"2015","journal-title":"Chem. -Biol. Interact."},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib29","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1038\/s41598-022-08461-0","article-title":"BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling","volume":"12","author":"Bradbury","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2026.119821_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.trecan.2021.12.003","article-title":"When breaks get hot: inflammatory signaling in BRCA1\/2-mutant cancers","volume":"8","author":"van Vugt","year":"2022","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119821_bib31","article-title":"Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse","volume":"5","author":"Chen","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119821_bib32","doi-asserted-by":"crossref","first-page":"a014241","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119821_bib33","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3390\/cancers11122043","article-title":"A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells","volume":"11","author":"Brachet-Botineau","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2026.119821_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1567","article-title":"Dormant cancer cells and polyploid giant cancer cells: the roots of cancer recurrence and metastasis","volume":"14","author":"Jiao","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.18632\/oncotarget.5834","article-title":"The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer","volume":"7","author":"Stine","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.biopha.2026.119821_bib36","doi-asserted-by":"crossref","first-page":"12358","DOI":"10.18632\/oncotarget.2590","article-title":"Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells","volume":"5","author":"Jaganathan","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.biopha.2026.119821_bib37","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/0008-5472.CAN-21-2342","article-title":"AMPK\u2013mTOR\u2013Mediated activation of autophagy promotes formation of dormant polyploid giant cancer cells","volume":"82","author":"You","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119821_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.795762","article-title":"Emerging roles of aldehyde dehydrogenase isoforms in anti-cancer therapy resistance","volume":"9","author":"Zanoni","year":"2022","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/ijms26010251","article-title":"The significance of aldehyde dehydrogenase 1 in cancers","volume":"26","author":"Nguyen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"59","key":"10.1016\/j.biopha.2026.119821_bib40","doi-asserted-by":"crossref","first-page":"99382","DOI":"10.18632\/oncotarget.19544","article-title":"Inhibition of aldehyde dehydrogenase 1 enhances the cytotoxic effect of retinaldehyde on A549 cancer cells","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119821_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108727","article-title":"Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines","volume":"113","author":"Yang","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2026.119821_bib42","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119821_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"New. Engl. J. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:48:36Z","timestamp":1787179716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S0753332226008577"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119821","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP inhibition induces a redox-dependent dormant reservoir vulnerable to disulfiram in high-grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119821"}}